Arecor Therapeutics PLC's (AIM:AREC) decision to close its Tetris Pharma subsidiary marks a significant strategic pivot, allowing the company to reallocate resources toward its high-value diabetes programmes.
Analysts at Panmure Liberum view the move as an opportunity to capitalise on Arecor’s proprietary ultra-concentrated insulin formulations, AT278 and AT247, which they see as the cornerstone of the company’s value.
With discussions underway with potential co-development partners, management’s determination to maintain control over these assets underscores its confidence in their long-term commercial potential.
Tetris, which marketed the glucagon injection Ogluo, faced profitability delays due to persistent supply chain pressures and challenging pricing conditions.
The closure, which comes with a £3 million one-time charge, largely non-cash, reflects Arecor’s broader strategy to streamline operations and prioritise high-margin, innovation-driven opportunities.
The company’s renewed focus on its diabetes portfolio positions it to address a critical global healthcare need. AT278, an ultra-concentrated insulin aimed at simplifying treatment regimens for patients requiring high doses, is particularly promising.
Meanwhile, preclinical work on an oral GLP-1 receptor agonist, targeting obesity and metabolic disorders, represents another avenue for long-term growth in the expanding metabolic health market.
While the short-term impact of the closure has prompted Panmure Liberum to revise its target price for Arecor from 361p to 324p, the analyst remains optimistic about the company’s prospects.
By refocusing its strategy, Arecor appears well-positioned to enhance operational efficiency and deliver sustained value through its innovative therapies, cementing its place in the competitive pharmaceutical landscape.